Stat4Onc
2019 Symposium Short Courses
April 25,
2019
Morning courses 8:30 AM to 12:00
noon with one break
Afternoon
courses 1:30 PM to 5:00
PM
with one break
Course 2 (Morning Course) Review of Early Phase Trial designs with
Recent Development for Precision Oncology
Instructor – Professor Ying Kuen
K. Cheung, Columbia University
Abstract:
Applications in early phase cancer trials have motivated the
development of many statistical designs since the late 1980s, including
futility screening, dose finding methods, treatment selection, and early
stopping rules. These methods are often proposed to address the
conventional cytotoxic therapeutics for neoplastic diseases and cancer.
In contrast, recent advances in precision medicine have motivated novel trial
designs, most notably the idea of master protocol (e.g., basket trial, platform
trial, “N-of-1”, etc.), for the evaluation of molecularly targeted cancer
therapies. In this short course, we will have a quick review of trial concepts
from these two sets of literature. We will discuss when and how the
designs and the principles developed for cytotoxic agents may be relevant for
targeted cancer therapies. We will also suggest open design questions
that call for further research.
Biography
Ying Kuen
(Ken) Cheung, PhD, is Professor and Interim Chair of Biostatistics in the
Mailman School of Public Health at Columbia University. He has general
interests in the development and evaluation of evidence-based treatments,
interventions and policies at all phases of translational research. An
overarching goal of his research and professional activities is to advance
precision medicine using data science and biostatistical methods. He led
a schoolwide task force on precision medicine that identified priority areas
crucial to the advances of the mission of precision public health. He is
also an expert in experimental designs, adaptive designs in clinical trials of
treatments for cancer, stroke, and other neurological disorders, SMART designs for
behavioral intervention technologies, N-of-1 personalized trials,
implementation study designs, and the analysis of high dimensional behavioral
data. He is a Fellow of the American Statistical Association, and a
Fellow of the New York Academy of Medicine. He is also a recipient of IBM
Faculty Award on Big Data and Analytics.